Glucagon therapeutics: Dawn of a new era for diabetes care

Diabetes/Metabolism Research and Reviews

Volumn 32, Issue 7, 2016, Pages 660-665

  Davidson, Jaime A ^a   Holland, William L ^a   Roth, Michael G ^a   Wang, May yun ^a   Lee, Young ^a   Yu, Xinxin ^a   McCorkle, Sara K ^b   Scherer, Philipp E ^a   Unger, Roger H ^a,b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b VA NORTH TEXAS HEALTH CARE SYSTEM   (United States)

Author keywords

diabetes; glucagon; glucagon receptor; haemoglobin A1c; insulin; treatment of diabetes; type 1 and type 2 diabetes

Indexed keywords

GLUCAGON; GLUCOSE; HEMOGLOBIN A1C; INSULIN;

BLOOD GLUCOSE MONITORING; DIABETES MELLITUS; DIABETIC KETOACIDOSIS; DIABETIC PATIENT; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; METABOLIC REGULATION; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATIENT CARE; PRIORITY JOURNAL; REVIEW;

EID: 84989851150     PISSN: 15207552     EISSN: 15207560     Source Type: Journal    
DOI: 10.1002/dmrr.2773     Document Type: Review

References (24)

1. Nathan DM, Cleary PA, Backlund JY, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005; 353(25): 2643–2653.
2. Cleary PA, Orchard TJ, Genuth S, et al. The effect of intensive glycemic treatment on coronary artery calcification in type 1 diabetic participants of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study. Diabetes 2006; 55: 3556–3565.
3. Gubitosi-Klug RA, Group DER. The diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: summary and future directions. Diabetes Care 2014; 37: 44–49.
4. Unger RH, Orci L. Paracrinology of islets and the paracrinopathy of diabetes. Proceedings of the National Academy of Sciences of the United States of America 2010; 107: 16009–16012.
5. Bonner-Weir S, Orci L. New perspectives on the microvasculature of the islets of Langerhans in the rat. Diabetes 1982; 31: 883–889.
6. Maruyama H, Hisatomi A, Orci L, Grodsky GM, Unger RH. Insulin within islets is a physiologic glucagon release inhibitor. J Clin Invest 1984; 74: 2296–2299.
7. Watanabe M, Hirose Y, Sugimoto M, Nakanishi M, Watanabe H, Shimada M. The distribution of tissue insulin receptors in the mouse by whole-body autoradiography. J Recept Res 1992; 12: 13–37.
8. Unger RH. Insulin–glucagon ratio. Isr J Med Sci 1972; 8(3): 252–257.
9. Unger RH. The Banting Memorial Lecture 1975. Diabetes and the alpha cell. Diabetes 1976; 25: 136–151.
10. Frid A, Hirsch L, Gaspar R, et al. New injection recommendations for patients with diabetes. Diabetes Metab 2010; 36: S3–S18.
11. Raskin P, Unger RH. Effect of insulin therapy on the profiles of plasma immunoreactive glucagon in juvenile-type and adult-type diabetics. Diabetes 1978; 27: 411–419.
12. Wang MY, Chen L, Clark GO, et al. Leptin therapy in insulin-deficient type I diabetes. Proceedings of the National Academy of Sciences of the United States of America 2010; 107: 4813–4819.
13. Wang MY, Yan H, Shi Z, et al. Glucagon receptor antibody completely suppresses type 1 diabetes phenotype without insulin by disrupting a novel diabetogenic pathway. Proceedings of the National Academy of Sciences of the United States of America 2015; 112: 2503–2508.
14. Cahill GF Jr. The Banting Memorial Lecture 1971. Physiology of insulin in man. Diabetes 1971; 20: 785–799.
15. Lee Y, Wang MY, Du XQ, Charron MJ, Unger RH. Glucagon receptor knockout prevents insulin-deficient type 1 diabetes in mice. Diabetes 2011; 60: 391–397.
16. Wang ZV, Mu J, Schraw TD, et al. PANIC-ATTAC: a mouse model for inducible and reversible beta-cell ablation. Diabetes 2008; 57: 2137–2148.
17. Yu X, Park BH, Wang MY, Wang ZV, Unger RH. Making insulin-deficient type 1 diabetic rodents thrive without insulin. Proceedings of the National Academy of Sciences of the United States of America 2008; 105: 14070–14075.
18. Dunning BE, Foley JE, Ahren B. Alpha cell function in health and disease: influence of glucagon-like peptide-1. Diabetologia 2005; 48: 1700–1713.
19. Sadry SA, Drucker DJ. Emerging combinatorial hormone therapies for the treatment of obesity and T2DM. Nat Rev Endocrinol 2013; 9: 425–433.
20. Lund A, Bagger JI, Christensen M, Knop FK, Vilsboll T. Glucagon and type 2 diabetes: the return of the alpha cell. Curr Diab Rep 2014; 14: 555.
21. Raskin P, Unger RH. Hyperglucagonemia and its suppression. Importance in the metabolic control of diabetes. The New England journal of medicine 1978; 299: 433–436.
22. Blackard WG, Nelson NC. Portal and peripheral vein immunoreactive insulin concentrations before and after glucose infusion. Diabetes 1970; 19: 302–306.
23. Sindelar DK, Chu CA, Venson P, Donahue EP, Neal DW, Cherrington AD. Basal hepatic glucose production is regulated by the portal vein insulin concentration. Diabetes 1998; 47: 523–529.
24. Edgerton DS, Moore MC, Winnick JJ, et al. Changes in glucose and fat metabolism in response to the administration of a hepato-preferential insulin analog. Diabetes 2014; 63: 3946–3954.